N-glycosylation stabilizes CD155, helping colorectal tumors evade NK-cell surveillance

Colorectal cancer may be using a molecular disguise to slip past one of the immune system’s most aggressive patrols. A study by Xu, Zhang, Yang and colleagues, published in Cell Death Discovery, reports that N-glycosylation—a biochemical modification in which sugar structures are attached to proteins—stabilizes the immune-regulatory molecule CD155 on colorectal cancer cells. By preserving CD155 at the tumor-cell surface, this process may help malignant cells evade surveillance by natural killer, or NK, cells, immune defenders specialized in recognizing and destroying stressed, infected, or transformed cells. The findings offer a mechanistic explanation for how a cancer-associated surface protein can remain active long enough to weaken antitumor immunity.

CD155, also known as poliovirus receptor or PVR, is a cell-surface adhesion and signaling protein whose role in cancer is more complex than its name might suggest. In healthy tissues, CD155 participates in interactions between cells and can help regulate immune communication. In many tumors, however, its abundance is increased. The protein can bind receptors on immune cells, including the activating receptor DNAM-1 and inhibitory receptors such as TIGIT and CD96. The balance among these interactions influences whether an NK cell becomes activated, releases toxic granules, and kills a target—or receives signals that restrain its response. A tumor that maintains high levels of CD155 can therefore alter the molecular conversation at the immune synapse.

The new research focuses on what happens to CD155 after it has been produced by a cancer cell. N-glycosylation occurs when carbohydrate chains are enzymatically attached to specific asparagine residues as a protein moves through the endoplasmic reticulum and Golgi apparatus. This modification can affect a protein’s folding, trafficking, half-life, and ability to interact with other molecules. It is not simply a decorative coating. For membrane proteins, glycosylation can determine whether they reach the cell surface, how long they remain there, and whether they are protected from degradation. In the case of CD155, the study links this sugar-based processing to greater protein stability, creating a more persistent immune-evasion signal on colorectal cancer cells.

That connection is important because the amount of a protein inside a tumor cell does not necessarily predict its impact on immunity. A molecule may be synthesized in large quantities but rapidly removed from the cell surface, limiting its ability to contact immune receptors. Conversely, a stabilized membrane protein can continuously engage immune cells in the tumor microenvironment. By supporting CD155’s persistence, N-glycosylation may extend the period during which cancer cells can deliver inhibitory signals to NK cells. The result is a potential molecular shield: not an invisible tumor, but one that is better equipped to dampen the attack once immune cells arrive.

NK cells are particularly relevant to this process because they do not require the same antigen-specific priming as conventional cytotoxic T cells. They survey tissues for patterns associated with cellular stress, infection, or malignant transformation. When activated, they form an immune synapse with a target cell and release perforin and granzymes, proteins that initiate target-cell death. They also produce cytokines such as interferon-gamma, which can shape broader antitumor responses. Tumors survive when they prevent this sequence from beginning, disrupt the immune synapse, or suppress the signals that trigger cytotoxicity. Persistent CD155 may contribute to that suppression by favoring inhibitory receptor engagement over activating signals.

The study’s central implication is that the glycosylation machinery of a tumor cell may be as relevant to immune escape as the immune checkpoints themselves. Cancer therapies have traditionally concentrated on blocking receptors or ligands that restrain immune cells. The reported mechanism suggests another point of intervention upstream: preventing CD155 from being correctly processed, transported, or maintained at the cell surface. In principle, disrupting the relevant glycosylation sites or the enzymes that install N-glycans could make CD155 less stable and more vulnerable to turnover. Such an approach would need to be carefully designed, because glycosylation controls thousands of proteins in normal cells and broad interference could cause substantial toxicity.

The findings also raise the possibility of combining strategies that target CD155 biology with existing immunotherapies. If glycosylation-dependent stabilization keeps CD155 abundant, blocking an inhibitory receptor such as TIGIT might be more effective when the ligand is simultaneously reduced or destabilized. Alternatively, therapies aimed at tumor-specific glycosylation patterns could expose colorectal cancer cells to stronger NK-cell pressure while limiting effects on healthy tissues. These ideas remain dependent on the precise experimental evidence, clinical context, and safety profile of any proposed intervention. A mechanism identified in cultured cells or experimental models must still be validated in patient tumors, where oxygen levels, nutrient availability, stromal cells, macrophages, and treatment history can all reshape glycosylation and immune behavior.

Colorectal tumors are biologically diverse, and CD155 regulation may not be uniform across patients. Genetic alterations, inflammatory signals, metabolic conditions, and the composition of the tumor microenvironment can influence both glycosyltransferase activity and immune-cell function. Some cancers may rely heavily on glycosylation to preserve CD155, whereas others may use additional pathways to suppress NK cells. This variability makes CD155 glycosylation potentially valuable not only as a therapeutic target but also as a biomarker. Measuring CD155 abundance, its glycan status, or the expression of relevant glycosylation enzymes could eventually help identify tumors with a particularly strong CD155-mediated immune-evasion program.

The report adds to a growing view of cancer as an ecosystem in which molecular modifications determine who can communicate with whom—and with what consequences. Glycosylation is increasingly recognized as a major regulator of tumor progression, affecting receptors, transporters, adhesion molecules, and immune checkpoints. By connecting this biochemical layer to CD155 stability and NK-cell surveillance, the study highlights how a seemingly small change in protein processing can have system-wide consequences for immune recognition. The discovery does not mean that a single sugar structure explains colorectal cancer’s resistance to immunity, but it identifies a potentially actionable link between tumor-cell metabolism, surface-protein stability, and immune escape.

For patients, the significance of the findings will ultimately depend on whether this pathway can be manipulated selectively and safely. The next steps will likely include defining the exact N-glycosylation sites that control CD155 stability, identifying the enzymes responsible, testing whether disrupting the modification restores NK-cell killing, and determining how the pathway behaves in human colorectal cancer samples. Researchers will also need to establish whether the mechanism affects other immune cells or interacts with chemotherapy, targeted drugs, and checkpoint inhibitors. If those questions are answered, the sugar coating that helps colorectal cancer preserve CD155 could become more than a molecular curiosity: it could represent a new vulnerability in tumors that have learned to survive under immune surveillance.